Brazil revokes permit granted to Israeli antiviral spray

No studies available are said to demonstrate efficiency

Published in 19/01/2022 - 13:22 By Pedro Peduzzi - Brasília

Brazil’s national drug regulator Anvisa canceled the authorization granted to antiviral spray Taffix late in December. No trials have been presented, Anvisa declared, demonstrating the efficiency of the Israeli product, manufactured by company Nasuspharma.

“The product was alleged to serve to block virus in the nasal cavity and to be efficient in blocking a number of respiratory viruses, including Sars-CoV-2. However, no clinical studies proving its efficiency for this end have been presented, which makes its immediate cancellation necessary,” the watchdog stated.

Companies wishing to regularize antiviral sprays, Anvisa went on to declare, “must demonstrate all proposed recommendations for use through clinical studies.” The irregularity was identified while auditing for compliance and health requirements.

Translation: Fabrício Ferreira -  Edition: Graça Adjuto

Latest news